This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 13.11% and 4.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
by Zacks Equity Research
Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -50% and 13.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
by Zacks Equity Research
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
by Zacks Equity Research
Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.
Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -9.68% and 3.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -37.50% and 11.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Universal Health (UHS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Universal Health Services' (UHS) first-quarter results are likely to reflect the benefits of increased admissions.
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 27.27% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?